You are here

  • Home
  • Archive
  • Volume 96, Issue 11
  • Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital: summary of the NICE guideline

Article Text

Article menu
Download PDFPDF
Technology and guidelines
Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital: summary of the NICE guideline

https://doi.org/10.1136/hrt.2010.198275

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • This work was undertaken by the National Clinical Guidelines Centre which received funding from the National Institute for Health and Clinical Excellence. The views expressed in this publication are those of the authors and not necessarily those of the Institute.

    • Declaration: A similar summary to this was published in the BMJ 2010;340:c95.

    • Funding The NCGC is funded by the National Institute for Health and Clinical Excellence.

    • Competing interests Both JH and TT have support from NICE for work on guideline development. JH and her department are funded by NICE and TT receives honorariums for chairing guideline development group meetings.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • ↵i Prescribers should consult the summary of product characteristics for the pharmacological VTE prophylaxis being used or planned for further details.

    • ↵ii At the time of publication (2010) some types of LMWH do not have UK marketing authorisation for VTE prophylaxis in medical patients. Prescribers should consult the summary of product characteristics for the individual LMWH. Informed consent for off-label use should be obtained and documented.